Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Dan Atar,
Hans Erik Botker,
By Dan Atar, FESC (Oslo, Norway)View Discussant report
Read the press releaseOpen the PresentationWatch the WebcastResources are published as they become available during the congress
List of Authors: D. Atar(1), H. Arheden (2), P. Clemmensen (3), N. Danchin (4), D. Erlinge (5), H. Firat (6), S. Halvorsen (1), W. Hauke (7), E. Vicaut (8), S. Eggert Jensen (9)
(1) Oslo University Hospital, Dept of Cardiology B, Oslo, Norway; (2) Skane University Hospital, Dept. of Clinical Physiology, Lund, Sweden; (3) Rigshospitalet, Copenhagen University Hospital, Dept. of Cardiology, Copenhagen, Denmark(4) European Hospital Georges Pompidou, Dept. of Cardiology, Paris, France (5) Skane University Hospital, Dept. of Cardiology, Lund, Sweden (6) FIRALIS SAS, Huningue, France (7) Trophos SA, Luminy Biotech Enterprises, Marseille, France (8) Hospital Lariboisiere, Clinical Research Unit, Paris, France (9) Aalborg University Hospital, Dept. of Cardiology, Aalborg, Denmark
Aims:The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI).Methods:Patients presenting with STEMI within 6 hours of onset of pain randomly received TRO40303 (n=83) or placebo (n=80) via intravenous bolus injection prior to balloon inflation during primary PCI in a double-blind manner. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and for troponin I (TnI) over three days. Secondary endpoints included measures of infarct size using cardiac magnetic resonance (CMR) and safety outcomes.Results:Median pain-to-balloon time was 180 minutes for both groups, and median (mean) door-to-balloon time was 60 (38) minutes for all sites. Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. There were no significant differences in CMR-assessed myocardial salvage index (1-infarct size/myocardium at risk) (mean 52% vs. 58% with placebo, p=0.1000), mean CMR-assessed infarct size (21.9 g vs. 20.0 g, or 17% vs. 15% of LV-mass) or left ventricular ejection fraction (LVEF) (46% vs 48%), or in the mean 30-day echocardiographic LVEF (51.5% vs 52.2%) between TRO40303 and placebo. A greater number of adjudicated safety events occurred in the TRO40303 group for unexplained reasons.Conclusions:This study in STEMI patients treated with contemporary mechanical revascularization principles did not show any effect of TRO40303 in limiting reperfusion injury of the ischemic myocardium
By Hans Erik Botker, FESC (Aarhus N, Denmark)See Presenter abstractOpen the presentationWatch the Webcast
Hot Line: Myocardial Infarction
© 2017 European Society of Cardiology. All rights reserved